3.1 Distance from BSMs to small-molecule drugs
The most important reason to study BSMs is that it provides an
opportunity to be a potential medicine and clinical intervention.
Although the development of bio-macromolecule drugs represented by
monoclonal antibodies, such as PD-1 [85], is quite predominant at
present, small-molecular drug holds about an 80% share of the global
drug market. And since the monoclonal antibodies are complicated to
product and difficult to store, the heterogeneity among the
effectiveness of the drugs obtained by different methods limits its wide
use. Hence, the drugs derived from BSMs would a good alternative in
cardiovascular fields.